What is Osteogenesis imperfecta?
Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a rare genetic connective tissue disorder characterized by bones that break easily with minimal or no trauma. The condition primarily affects the production of type I collagen, the most abundant protein in bones, skin, and other connective tissues. OI occurs in approximately 1 in 15,000 to 20,000 births worldwide, affecting people of all ethnic backgrounds equally. While severity varies considerably, most individuals with OI experience frequent fractures throughout their lives, along with other characteristic features affecting the eyes, teeth, and hearing.
Key statistics
| Prevalence | 1 in 15,000–20,000 births |
| Inheritance pattern | Autosomal dominant (85-90%), autosomal recessive (10-15%) |
| Age of onset | Birth (congenital), though diagnosis may be delayed |
| Life expectancy | Near normal in mild forms; reduced in severe forms |
Symptoms
Primary symptoms: Recurrent fractures, blue or gray sclerae, dentinogenesis imperfecta, hearing loss, short stature, bone deformities, loose joints, fragile skin.
The hallmark of OI is bone fragility leading to fractures from minimal trauma or even normal daily activities. Blue or gray sclerae (the white part of the eyes) occur due to the thin collagen allowing underlying blood vessels to show through. Dentinogenesis imperfecta affects tooth development, causing discolored, translucent, or brittle teeth that wear down easily.
Progressive hearing loss typically begins in the second or third decade of life, affecting up to 90% of adults with OI. Short stature is common, with adult height often significantly below average. Bone deformities may include bowing of the legs, spinal curvature (scoliosis or kyphosis), and chest wall abnormalities.
Joint hypermobility and ligamentous laxity are frequent, leading to joint pain and increased injury risk. Skin may be thin, translucent, and prone to easy bruising. Some individuals experience excessive sweating, respiratory complications due to chest wall deformities, and cardiovascular issues including mitral valve prolapse.
The severity ranges dramatically from type I (mildest) with normal lifespan and mild bone fragility, to type II (most severe) which is often lethal in infancy due to severe bone deformities and respiratory complications.
Causes and risk factors
OI is primarily caused by mutations in genes responsible for type I collagen production and processing. Approximately 85-90% of cases result from autosomal dominant mutations in either the COL1A1 or COL1A2 genes, which encode the alpha chains of type I collagen. These mutations either reduce the amount of normal collagen produced or create structurally abnormal collagen.
Additional genes associated with OI include CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, PLOD2, BMP1, TMEM38B, WNT1, CREB3L1, SPARC, and MBTPS2, accounting for autosomal recessive and X-linked forms. These genes are involved in collagen modification, folding, and bone formation pathways.
The main risk factor is having an affected parent, as most cases are inherited. However, approximately 25-30% of cases result from de novo (new) mutations with no family history. Advanced parental age may slightly increase the risk of new mutations, though this association is not as strong as in some other genetic conditions.
Prevention
As OI is a genetic condition, primary prevention is not possible. However, genetic counseling and testing can help families understand inheritance patterns and reproductive risks. For families with a known OI history, preimplantation genetic diagnosis (PGD) or prenatal testing through chorionic villus sampling or amniocentesis may be options.
Carrier testing is not applicable for autosomal dominant forms, as carriers are affected. For autosomal recessive forms, carrier frequency varies by population but is generally low given the rarity of the condition. Genetic counseling is essential for family planning decisions and understanding the 50% recurrence risk for each pregnancy when one parent has autosomal dominant OI.
Secondary prevention focuses on fracture prevention through environmental modifications, appropriate physical activity, and medical management to strengthen bones and reduce fracture risk.
Complications
Without proper management, OI can lead to severe complications affecting multiple organ systems. Repeated fractures may result in progressive bone deformities, chronic pain, and mobility limitations. Spinal complications include scoliosis, kyphosis, and basilar invagination (upward displacement of the upper cervical spine), which can compress the brainstem and cause neurological symptoms.
Respiratory complications arise from chest wall deformities, rib fractures, and spinal curvature, potentially leading to restrictive lung disease and increased pneumonia risk. Cardiovascular complications may include mitral valve prolapse, aortic root dilation, and other structural heart abnormalities.
Progressive hearing loss can significantly impact communication and quality of life. Dental complications from dentinogenesis imperfecta may require extensive dental work and can affect nutrition and self-esteem. Mobility limitations may lead to decreased bone density from reduced weight-bearing activity, creating a cycle of increased fracture risk.
Psychosocial complications include anxiety around fracture risk, social isolation, depression, and challenges with independence and employment.
Diagnosis
OI diagnosis combines clinical evaluation, family history, imaging studies, and genetic testing. Clinical criteria include recurrent fractures with minimal trauma, characteristic skeletal deformities, blue sclerae, dentinogenesis imperfecta, hearing loss, and family history.
Radiographic findings include osteopenia (low bone density), gracile bones with thin cortices, vertebral compression fractures, and characteristic deformities. Dual-energy X-ray absorptiometry (DEXA) scans assess bone mineral density, though interpretation requires age-appropriate reference ranges.
Genetic testing can identify mutations in known OI genes, providing definitive diagnosis and enabling family counseling. However, negative genetic testing does not rule out OI, as some causative genes may not yet be identified.
Biochemical testing of cultured skin fibroblasts can assess collagen production and structure, though this specialized testing is less commonly used since genetic testing became widely available. Bone biopsy may occasionally be performed for research purposes or in unclear cases.
Prenatal diagnosis through ultrasound may detect severe skeletal abnormalities, though mild forms may not be detectable prenatally.
Treatment
Treatment focuses on fracture prevention, pain management, maximizing function, and addressing complications. Bisphosphonates are the primary medical therapy, including pamidronate and zoledronic acid, which increase bone density and reduce fracture rates by 30-50%.
Physical therapy emphasizes safe strengthening exercises, mobility training, and adaptive techniques. Occupational therapy addresses daily living skills and environmental modifications. Swimming and water-based exercises are particularly beneficial as they provide resistance training while minimizing fracture risk.
Surgical interventions include intramedullary rodding for long bone fractures and deformities, spinal fusion for severe scoliosis, and basilar invagination correction when neurological symptoms are present. Dental care addresses dentinogenesis imperfecta through protective treatments, crowns, and sometimes complete dental reconstruction.
Hearing aids or cochlear implants may be necessary for progressive hearing loss. Pain management typically involves acetaminophen, nonsteroidal anti-inflammatory drugs (with caution due to potential effects on bone healing), and sometimes stronger analgesics for acute fractures.
Assistive devices including wheelchairs, walkers, and braces may enhance mobility and independence while reducing fracture risk.
Prognosis
Prognosis varies significantly based on OI type and severity. Individuals with type I OI typically have normal or near-normal life expectancy with good quality of life, experiencing fewer fractures after puberty. Type IV OI has variable severity but generally allows for independent living with appropriate management.
Type III OI, the most severe non-lethal form, requires intensive management and often results in significant physical limitations, though many individuals achieve meaningful independence and career success. Type II OI is typically lethal in infancy due to severe skeletal deformities and respiratory insufficiency.
With modern medical management including bisphosphonate therapy, physical therapy, and improved surgical techniques, outcomes have improved significantly. Many individuals with OI pursue higher education, maintain employment, and lead fulfilling lives. However, the condition requires lifelong management and vigilance for complications.
Factors influencing prognosis include early diagnosis, access to specialized care, family support, and individual response to treatment.
Quality of life
Living with OI requires adaptations but many individuals achieve excellent quality of life. Environmental modifications include removing throw rugs, installing grab bars, using appropriate car seats and seat belts, and choosing suitable recreational activities. Swimming, wheelchair sports, and other low-impact activities can provide exercise benefits while minimizing fracture risk.
Nutrition focuses on adequate calcium and vitamin D intake, though supplements should be discussed with healthcare providers. Maintaining healthy body weight reduces stress on bones while avoiding malnutrition that could impair bone health.
Sleep quality may be affected by chronic pain and positioning challenges, requiring appropriate mattresses and positioning aids. Mental health support is important, as chronic conditions can impact mood and anxiety levels. Many individuals benefit from counseling and peer support groups.
Educational and workplace accommodations may include modified physical activities, ergonomic equipment, and emergency action plans for fractures. Many successful professionals with OI work in various fields, demonstrating that career limitations are often surmountable with proper support and accommodations.
Pregnancy and fertility
Fertility is typically normal in individuals with OI, though pregnancy requires specialized management due to potential complications. Maternal fracture risk may increase due to calcium demands of pregnancy and physical changes. Pelvic fractures or deformities may necessitate cesarean delivery.
Bisphosphonate therapy should be discontinued before conception due to potential fetal effects, requiring careful timing and alternative bone protection strategies. Genetic counseling is essential, as autosomal dominant OI carries a 50% risk of transmission to offspring.
Prenatal monitoring includes serial ultrasounds to assess fetal skeletal development, though mild OI may not be detectable prenatally. Some couples choose preimplantation genetic diagnosis to avoid transmitting the condition.
Breastfeeding is generally safe and encouraged, though attention to maternal nutrition and bone health is important during lactation.
Children
Pediatric OI management focuses on fracture prevention, promoting normal development, and family education. Parents learn safe handling techniques, appropriate activities, and fracture recognition. School personnel require education about the condition and emergency protocols.
Physical therapy begins early to promote muscle strength and motor development while teaching safe movement patterns. Bisphosphonate therapy in children requires careful monitoring, as effects on growing bones are still being studied.
Psychosocial support helps children cope with activity restrictions and peer relationships. Many children with OI participate successfully in school activities with appropriate modifications and achieve normal developmental milestones.
When to see a doctor
Immediate medical attention is needed for suspected fractures, severe pain, deformity, inability to bear weight, or neurological symptoms suggesting spinal complications. Signs include severe headache, neck pain, weakness, numbness, or changes in consciousness that might indicate basilar invagination.
Routine follow-up should occur every 6-12 months with specialists familiar with OI, including orthopedics, endocrinology, and genetics. Regular monitoring includes bone density scans, hearing assessments, cardiac evaluations, and dental care.
New or worsening symptoms such as progressive hearing loss, dental problems, or respiratory difficulties warrant prompt evaluation. Children require regular growth monitoring and developmental assessments.
Regional context
Limited specific data exists for OI prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. Given the genetic nature of OI and relatively stable prevalence across populations, rates likely approximate global figures of 1 in 15,000-20,000 births. However, access to specialized care, genetic testing, and treatments like bisphosphonates may vary significantly across the region.
Global Medical Journal invites healthcare professionals and researchers from the Caucasus and Eastern Mediterranean regions to contribute regional data and insights about OI management and outcomes in these populations.
Research and clinical trials
Current research focuses on novel therapies targeting different aspects of bone formation and collagen production. Gene therapy approaches aim to introduce normal collagen genes or silence defective ones. Stem cell research investigates bone marrow transplantation and mesenchymal stem cell therapy to improve bone formation.
New drug targets include sclerostin inhibitors, parathyroid hormone analogs, and anti-resorptive agents beyond bisphosphonates. Clinical trials are exploring transforming growth factor-beta inhibitors and Wnt signaling pathway modulators.
ClinicalTrials.gov lists ongoing studies investigating various therapeutic approaches. Recent breakthroughs include better understanding of OI genetics and collagen biology, leading to more targeted therapies and improved diagnostic capabilities.
Frequently asked questions
Can people with OI exercise safely?
Yes, appropriate exercise is important for bone and muscle health. Swimming, water aerobics, and supervised resistance training are generally safe. Avoid high-impact activities and contact sports. Physical therapists familiar with OI can design safe exercise programs.
Will my child’s fractures decrease with age?
In many types of OI, fracture frequency decreases after puberty due to hormonal changes and increased bone mass. However, fractures may increase again later in life, particularly in women after menopause.
Are there dietary restrictions for people with OI?
No specific restrictions exist, but adequate calcium and vitamin D intake is important for bone health. Maintain a balanced diet and discuss supplementation with your healthcare provider.
Can women with OI safely have children?
Many women with OI have successful pregnancies, though specialized medical care is essential. Discuss risks and management strategies with healthcare providers before conception.
Is OI always inherited?
No, approximately 25-30% of cases result from new mutations with no family history. However, these individuals can still pass the condition to their children.
Support and resources
- Osteogenesis Imperfecta Foundation – Primary patient organization providing education, support, and research funding
- Orphanet – Comprehensive rare disease database
- National Organization for Rare Disorders (NORD)
- EURORDIS – European rare disease patient advocacy
- World Health Organization (WHO) – Global health information and initiatives
Related conditions
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Osteogenesis imperfecta.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/osteogenesis-imperfecta/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?